Client News

Carbios accelerates its enzyme optimization with screening capabilities for millions of enzymes in a day

Abivax reports two-year efficacy and safety data of obefazimod phase 2b maintenance trial in ulcerative colitis

InflaRx announces closing of $40 million public offering of ordinary shares

Heidelberg Pharma AG: Interim management statement on the first three months of 2023

Destiny Pharma: Audited results for the year ended 31 December 2022

Andera Partners leads $48.5 Million Series A financing for medical device company BioVentrix®

Rentschler Biopharma appoints Thomas aus dem Siepen as Global Head Digital Manufacturing and Automation

ONWARD to attend upcoming scientific and investor events

InflaRx announces pricing of $40 Million public offering of ordinary shares

InflaRx announces public offering of ordinary shares